220 related articles for article (PubMed ID: 38365950)
1. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
Björk JR; Bolte LA; Maltez Thomas A; Lee KA; Rossi N; Wind TT; Smit LM; Armanini F; Asnicar F; Blanco-Miguez A; Board R; Calbet-Llopart N; Derosa L; Dhomen N; Brooks K; Harland M; Harries M; Lorigan P; Manghi P; Marais R; Newton-Bishop J; Nezi L; Pinto F; Potrony M; Puig S; Serra-Bellver P; Shaw HM; Tamburini S; Valpione S; Waldron L; Zitvogel L; Zolfo M; de Vries EGE; Nathan P; Fehrmann RSN; Spector TD; Bataille V; Segata N; Hospers GAP; Weersma RK
Nat Med; 2024 Mar; 30(3):785-796. PubMed ID: 38365950
[TBL] [Abstract][Full Text] [Related]
2. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
Bolte LA; Lee KA; Björk JR; Leeming ER; Campmans-Kuijpers MJE; de Haan JJ; Vila AV; Maltez-Thomas A; Segata N; Board R; Harries M; Lorigan P; de Vries EGE; Nathan P; Fehrmann R; Bataille V; Spector TD; Hospers GAP; Weersma RK
JAMA Oncol; 2023 May; 9(5):705-709. PubMed ID: 36795408
[TBL] [Abstract][Full Text] [Related]
3. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.
Usyk M; Pandey A; Hayes RB; Moran U; Pavlick A; Osman I; Weber JS; Ahn J
Genome Med; 2021 Oct; 13(1):160. PubMed ID: 34641962
[TBL] [Abstract][Full Text] [Related]
4. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E; Kowall B; Hassel JC; Schilling B; Sachse M; Gutzmer R; Loquai C; Kähler KC; Hüsing A; Gilde C; Thielmann CM; Zaremba-Montenari A; Placke JM; Gratsias E; Martaki A; Roesch A; Ugurel S; Schadendorf D; Livingstone E; Stang A; Zimmer L
Eur J Cancer; 2024 Mar; 200():113536. PubMed ID: 38306840
[TBL] [Abstract][Full Text] [Related]
5. A gut microbial signature for combination immune checkpoint blockade across cancer types.
Gunjur A; Shao Y; Rozday T; Klein O; Mu A; Haak BW; Markman B; Kee D; Carlino MS; Underhill C; Frentzas S; Michael M; Gao B; Palmer J; Cebon J; Behren A; Adams DJ; Lawley TD
Nat Med; 2024 Mar; 30(3):797-809. PubMed ID: 38429524
[TBL] [Abstract][Full Text] [Related]
6. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
7. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma.
Wind TT; Gacesa R; Vich Vila A; de Haan JJ; Jalving M; Weersma RK; Hospers GAP
Melanoma Res; 2020 Jun; 30(3):235-246. PubMed ID: 31990790
[TBL] [Abstract][Full Text] [Related]
8. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA; Thomas AM; Bolte LA; Björk JR; de Ruijter LK; Armanini F; Asnicar F; Blanco-Miguez A; Board R; Calbet-Llopart N; Derosa L; Dhomen N; Brooks K; Harland M; Harries M; Leeming ER; Lorigan P; Manghi P; Marais R; Newton-Bishop J; Nezi L; Pinto F; Potrony M; Puig S; Serra-Bellver P; Shaw HM; Tamburini S; Valpione S; Vijay A; Waldron L; Zitvogel L; Zolfo M; de Vries EGE; Nathan P; Fehrmann RSN; Bataille V; Hospers GAP; Spector TD; Weersma RK; Segata N
Nat Med; 2022 Mar; 28(3):535-544. PubMed ID: 35228751
[TBL] [Abstract][Full Text] [Related]
9. The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD; Hurd D; Davar D
Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
[TBL] [Abstract][Full Text] [Related]
10. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
Thompson NA; Stewart GD; Welsh SJ; Doherty GJ; Robinson MJ; Neville BA; Vervier K; Harris SR; Adams DJ; Dalchau K; Bruce D; Demiris N; Lawley TD; Corrie PG
BMC Cancer; 2022 Jan; 22(1):99. PubMed ID: 35073853
[TBL] [Abstract][Full Text] [Related]
11.
Tomita Y; Goto Y; Sakata S; Imamura K; Minemura A; Oka K; Hayashi A; Jodai T; Akaike K; Anai M; Hamada S; Iyama S; Saruwatari K; Saeki S; Takahashi M; Ikeda T; Sakagami T
Oncoimmunology; 2022; 11(1):2081010. PubMed ID: 35655708
[TBL] [Abstract][Full Text] [Related]
12. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
13. Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota.
Bouferraa Y; Fares C; Bou Zerdan M; Boyce Kennedy L
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298653
[TBL] [Abstract][Full Text] [Related]
14. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Loo K; Smithy JW; Postow MA; Betof Warner A
Front Immunol; 2021; 12():810388. PubMed ID: 35087529
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
16. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract][Full Text] [Related]
17. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive Probiotic
Gao G; Ma T; Zhang T; Jin H; Li Y; Kwok LY; Zhang H; Sun Z
Front Immunol; 2021; 12():772532. PubMed ID: 34970262
[TBL] [Abstract][Full Text] [Related]
19. Probiotics
Wang T; Zheng N; Luo Q; Jiang L; He B; Yuan X; Shen L
Front Immunol; 2019; 10():1235. PubMed ID: 31214189
[TBL] [Abstract][Full Text] [Related]
20. Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review.
Halsey T; Ologun G; Wargo J; Jenq RR
Semin Hematol; 2020 Jan; 57(1):13-18. PubMed ID: 32690139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
